Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
A pilot study of 106 patients with “wet” AMD revealed that nearly half of patients treated with Eylea could safely stop therapy after one year, compared to only 17% of patients treated with Avastin.
A new study from Duke University finds that single neurons conveying visual information about two separate objects in sight do so by alternating signals about one or the other.
Researchers from the University of Illinois shed light on how neural stem cells called neuroblasts divide multiple times to sequentially produce neurons of specialized function.
Jordan Hamm, an assistant professor of neuroscience at Georgia State University, has received a five-year, $1.93 million award from the National Eye Institute.
Rogue clinics offer stem cell-based therapies that haven’t been tested for safety and efficacy. When communicating to the public about stem cell-based therapies, it is important to put any treatment claims in context.
Using a new stem-cell based model made from skin cells, scientists found the first direct evidence that Stargardt-related ABCA4 gene mutations affect a layer of cells in the eye called the retinal pigment epithelium (RPE).